country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-186311

Copy Link Print Information

IDB-003

IDB-003 is an orally active inhibitor of the human ribosomal peptidyl transferase center (PTC). IDB-003 exhibits antiproliferative activity against MYC-dependent cancer cells. IDB-003 binds to PTC, maintains ribosomal RNA interactions, blocks translation via context-dependent nascent polypeptide chain interactions, depletes MYC and CCND1, activates JNK phosphorylation through ribosomal collision, and downregulates the MYC target pathway. IDB-003 inhibits the growth of triple-negative breast cancer xenografts in mice. IDB-003 can be used for the research of triple-negative breast cancer.

For research use only. We do not sell to patients.

CAS No.: 3079716-11-0
Formula: C₂₂H₂₂FN₃O₄
Molecular Weight:411.43

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

IDB-003 Chemical Structure

CAS No.: 3079716-11-0

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All JNK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
22Rv1	EC50	0.042 μM	Antiproliferative activity against human 22Rv1 prostate cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay. Antiproliferative activity against human 22Rv1 prostate cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.	41735331
HCC1143	EC50	0.132 μM	Antiproliferative activity against human HCC-1143 triple-negative breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay. Antiproliferative activity against human HCC-1143 triple-negative breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.	41735331
LS-411N	EC50	0.021 μM	Antiproliferative activity against human LS411N colorectal cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay. Antiproliferative activity against human LS411N colorectal cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.	41735331
MCF7	EC50	0.096 μM	Antiproliferative activity against human MCF7 HR+/HER2- breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay. Antiproliferative activity against human MCF7 HR+/HER2- breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.	41735331
MRC5	EC50	0.331 μM	Antiproliferative activity against human MRC5 fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay. Antiproliferative activity against human MRC5 fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.	41735331

In Vitro

Anti-cancerCell Cycle RegulationOthers

Anti-cancer

IDB-003 (72 h) potently inhibits the proliferation of 22Rv1, HCC-1143, LS411N and MCF7 cancer cells (EC₅₀ values 0.021-0.132 μM), while exhibits weak activity against MRC5 fibroblasts (EC₅₀ 0.331 μM)^[1].

Cell Cycle Regulation

IDB-003 (1-10 μM; 2 h-<4 h) depletes the short-lived oncoproteins MYC and CCND1 in MCF7 cells: this depletion is achieved within 2-4 h at treatment concentrations of 1 μM and 10 μM, respectively, without altering the levels of the long-lived proteins CDK4 and tubulin^[1].

Anti-cancer

Cell Cycle Regulation

IDB-003 (2-72 h) depletes MYC protein in HCC-1143 cells in a concentration-dependent manner within 2 h, which correlates with reduced cell viability after 72 h of treatment^[1].

Others

IDB-003 (1.27 μM; 60 min) induces context-dependent translation arrest in HCC-1143 cells, preferentially targeting nascent polypeptide chains with an aliphatic residue at position −1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MCF7 breast cancer cells
Concentration:

1 μM (15 min-8 h incubations); 10 μM (<4 h incubation)
Incubation Time:

15 min, 30 min, 1 h, 2 h, 4 h, 8 h (1 μM); <4 h (10 μM)
Result:

Depleted CCND1 rapidly (evident by 1-2 h) and reduced MYC levels (observable after 2 h) at 1 μM.
Depleted MYC rapidly within <4 hours at 10 μM.
Left abundance of longer-lived proteins CDK4 and tubulin stable over the same time course.

In Vivo

Anti-cancerCell Cycle Regulation

Anti-cancer

Cell Cycle Regulation

IDB-003 (3-10 mg/kg, p.o., twice daily for 28 days) achieves a 58%-80% tumor growth inhibition rate in a mouse MDA-MB-231 triple-negative breast cancer xenograft model, accompanied by downregulation of the MYC target pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude mice (female, 6-8 weeks old)^[1]
Dosage:

3 mg/kg; 10 mg/kg
Administration:

p.o.; twice daily; 28 days (3 mg/kg); p.o.; twice daily; 11 days, followed by 2-day holiday, then resuming twice daily for remainder of 28 days (10 mg/kg)
Result:

Achieved 58% tumor growth inhibition (TGI) compared to vehicle control.
Achieved 80% tumor growth inhibition (TGI) compared to vehicle control.
Downregulated MYC targets v1 pathway as the most significantly altered pathway in endpoint tumor samples.

Related Protocols :

Chemical Information

CAS No. 3079716-11-0
Molecular Weight 411.43
Formula C₂₂H₂₂FN₃O₄
SMILES

FC1=CC=CC(CNC(O[C@H]([C@H](CN2)O)[C@H]2CC3=CC=C(C4=CN=CO4)C=C3)=O)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Diamond PD, et al. Context-dependent translation inhibition as a cancer therapeutic modality. Nature communications. 2026 Feb 24;17(1):1963. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

IDB-003

All JNK Isoforms

Biological Activity

Description

Cellular Effect

In Vitro

In Vivo

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

IDB-003 Related Classifications

HY-186311 Related Classifications

Bioz

Keywords

Your Recently Viewed Products